MedTrace Logo

Cerebral Oximetry in Newborns - Comparing INVOS 5100 and FORE-SIGHT Cerebral Oximeters

NCT01665287 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2013-01-15

No results posted yet for this study

Summary

Regional tissue oxygenation (rStO2) can be monitored by near infrared spectroscopy. The commercial devices FORE-SIGHT (CASMED) and INVOS (COVIDIEN) will be used simultaneously to test for their relative sensitivity for low oxygen levels just after birth on term infants born by elective cesarean section. Reproducibility will be examined by replacements of the sensors six times the next day when the infant is stable and quiet. Neonatal sensors will be used.

Conditions

  • Near Infrared Spectroscopy

Sponsors & Collaborators

  • The Augustinus Foundation, Denmark.

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Gorm Greisen, Professor · Not relevant

Eligibility

Max Age
2 Minutes
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Completion
2012-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01665287 on ClinicalTrials.gov